TRYbeCA-1 Phase 3 trial in second-line metastatic pancreatic cancer:More than 90% of the planned 500 patients enrolledFast-Track designation granted by […]
BRIDGEWATER, N.J., Sept. 21, 2020 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (NASDAQ: SNCR), a global leader and innovator of cloud, messaging, digital and […]